Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer (original) (raw)
References
Howell A, Dowsett M: Recent advances in the endocrine therapy of breast cancer. BMJ 315: 863–866, 1997 PubMed Google Scholar
Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E, Ruby E: Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocr Metab 47: 1257–1265, 1978 PubMed Google Scholar
Stuart-Harris R, Smith JE, Dowsett M, Bozek T, McKinna JA, Gazet J-C, Jeffcoate SL, Kurkure A, Carr L: Low-dose aminoglutethimide in treatment of advanced breast cancer. Lancet ii: 604–607, 1984 Google Scholar
Stuart-Harris RC, Smith IE: Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treatment Reviews 11: 189–204, 1984 PubMed Google Scholar
Kao C-Y, Can LL, Laughton CA, Zhou D, Chen S: Binding characteristics of seven inhibitors of human aromatase: a site directed mutagenesis study. Cancer Res 56: 3451–3460, 1996 PubMed Google Scholar
Coombes RC, Hughes SWM, Dowsett M: 4-hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer. Eur J Cancer 28A: 1941–1945, 1992 PubMed Google Scholar
Jones AL, MacNeill F, Jacobs S, Lonning PE, Dowsett M, Powles TJ: The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 28: 1712–1716, 1992 Google Scholar
Dowsett M, Jones A, Johnston SRD, Jacobs S, Trunet P, Smith IE: In vivo measurement of aromatase inhibition by letrozole (20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1: 1511–1515, 1995 PubMed Google Scholar
Geisler J, King N, Dowsett M, Ouestad L, Lundgren S, Walton P, Kormeset PO, Lonning PE: Influence of Anastrozole (Arimidexr) a non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma estrogen levels in postmenopausal women with breast cancer. Br J Cancer 74: 1286–1291, 1996 PubMed Google Scholar
Van der Wall E, Donker TH, DeGrankrijker E, et al.: Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women. Cancer Res 53: 4563–4566, 1993 PubMed Google Scholar
Marty M, Gershanovich M, Campos B, Romieu G, Lurie H, Bonaventura T, Jeffery M, Buzzi F, Ludwig H, Bodrogi I, Reichardt P, O'Higgins N, Chaudri HA, Friederich P, Blachoff MA: Letrozole, a new potent, selective aromatase inhibitor superior to aminoglutethimide in postmenopausal women with advanced breast cancer previously treated with antioestrogens [abstract] Proc Am Soc Clin Oncol 544: 156a, 1997 Google Scholar
Bergh J, Bonneterre J, Illiger HJ, Murray R, Nortier J, Paridaens R, Rubens RD, Samonigg H, Van Zyl J, Houston S: Vorozole (Rivizor) versus aminogluthimide (AG) in postmenopausal women with advanced breast cancer relapsing after tamoxifen [abstract]. Proc Am Soc Clin Oncol 543: 155a, 1997 Google Scholar
Klijn JGM, Seymour C, Beex L, et al.: Combined estrogen suppression and receptor blockade by buserelin (LHRH-A) and tamoxifen in premenopausal metastatic breast cancer: preliminary results of a 3-arm randomised study (EORTC 10881) Eur J Cancer 32A: 49 (abstr), 1996 Google Scholar
Jonat W, Kaufmann M, Blamey RW, Howell A, Collins JP, Coates A, Eiermann W, Janicke F, Njordenskold B, Forbes JF: A randomised study to compare the effect of the luterinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre-and postmenopausal patients with advanced breast cancer. Eur J Cancer 31A: 137–142, 1995 PubMed Google Scholar
Dowsett M, Cunningham D, Nicol, S, Lal A, Evans S, Brodie AMH, Jeffcoate SL, Coombes RC: Endocrinology and pharmacokinetics of oral 4-hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Steroids 50: 615–616, 1987 Google Scholar
Johnston SRD, Smith IE, Doody D, Jacobs S, Robertshaw H, Dowsett M: Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res 54: 5875–5881, 1994 PubMed Google Scholar
Ferguson K, Hayes M, Jeffcoate SL: A standardised multicentre procedure for plasma gonadotrophin radioimmunoassay. Ann Clin Biochem 19: 358–361, 1982 PubMed Google Scholar
Buzdar A, Jonat W, Howell A, Blomqvist C, Vogel CL, Eirmann W, Walter JM, Azab M, Webster A, Plourde PV: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 14: 2000–2011, 1996 PubMed Google Scholar
Dombernovsky P, Smith I, Falkson G, Panasci LL, Bezwoda W: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453–461, 1998 PubMed Google Scholar
Buzdar A, Jonat W, Howell A, Yin H, Lee D: Significant improved survival with Arimidex. Pro Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials [abstract]. Proc Am Soc Clin Oncol 545: 156a, 1997 Google Scholar
Goss P, Wine E, Tannock I, Schwartz IH, Kremer AB: Vorozole versus Megace in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen. Proc Am Soc Clin Oncol 542: 155a, 1997 Google Scholar
Holzman D: Elusive estrogens may hold key to some cancer risk. J Natl Cancer Inst 87: 1207–1209, 1995 PubMed Google Scholar
Dowsett M, Cunningham DC, Stein RC, Evans S, Dehennin L, Hedley A, Coombes RC: Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 49: 1306–1312, 1989 PubMed Google Scholar
MacNeill FA, Jones AL, Jacobs S, Lonning P, Powles TJ, Dowsett M: The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 66: 692–697, 1992 PubMed Google Scholar
Dowsett M: Theoretical considerations for the ideal aromatase inhibitor. Breast Cancer Res Treat 49: 539–544. 1998 Google Scholar
Dc Coster R, Tuman R, Bowden C, et al.: Endocrine effects of vorozole on pituitary-ovarian function. In: Motta M and Serio M (eds) Sex hormones and antihormones in endocrine dependent pathology: basic and clinical aspects. Elsevier, Amsterdam, 287–295, 1994 Google Scholar
Santen RJ, Samojlik E, Wells SA: Resistance of the ovary to blockade of aromatization with aminoglutethimide. J Clin Endocrinol Metab 51: 473-477, 180
Harris AL, Dowsett M, Jeffcoate SL, McKinna JA, Morgan M, Smith IE: Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab 55: 718–722, 1982 PubMed Google Scholar
Wander HE, Blossey HCL, Nagel GA. Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. Eur J Cancer 22: 1371–1374, 1986 Google Scholar
Wouters W, Dc Coster R, Tuman RW, Bowden CR, Bruynseels J, Vanderpas H, Van Rooy P, Amery WK, Janssen PAJ: Aromatase inhibition by R76713: experimental and clinical pharmacology. J Steroid Biochem 34: 427–430, 1989 PubMed Google Scholar
Stein RC, Dowsett M, Hedley A, Coombes RC: The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 62: 679–683, 1990 PubMed Google Scholar
Dowsett M, Stein RC, Coombes RC: Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem 43: 155–159, 1992 Google Scholar
Sakai F, Cheix F, Chavel M, Colon J, Mayer M: Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J Endocrinol 76: 219–226, 1978 PubMed Google Scholar
Wakeling AE, O'Connor KM, Newboult E: Comparison of the biological effects of tamoxifen and a new antioestrogen (LY 117018) on the immature rat uterus. J Endocrinol 99: 447–453, 1983 PubMed Google Scholar